Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.73 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluperlapine SCHEMBL30274851 | 1.00 | MAPK1 (1.00) | MAPK1HRH4PAK1CHRM1HRH1 | |
| SCHEMBL3411698 | 0.86 | MAPK1 (0.76) | MAPK1HRH4PAK1CHRM1HRH1 | |
| Perlapine SCHEMBL29397855 | 0.85 | HRH4 (1.00) | MAPK1HRH4HRH1DRD2DRD4 | |
| Perlapine SCHEMBL114768 | 0.85 | HRH4 (1.00) | MAPK1HRH4HRH1DRD2DRD4 | |
| SCHEMBL25462854 | 0.85 | MAPK1 (0.73) | MAPK1HRH4CHRM1HRH1DRD2 | |
| SCHEMBL13409920 | 0.85 | MAPK1 (0.73) | MAPK1HRH4CHRM1HRH1DRD2 | |
| SCHEMBL7412478 | 0.79 | HRH4 (0.74) | MAPK1HRH4PAK1CHRM1HRH1 | |
| SCHEMBL2615364 | 0.78 | CHRM1 (0.84) | MAPK1HRH4PAK1CHRM1HRH1 | |
| SCHEMBL2615365 | 0.78 | CHRM1 (0.84) | MAPK1HRH4PAK1CHRM1HRH1 | |
| SCHEMBL10621494 | 0.74 | MAPK1 (0.58) | MAPK1HRH4PAK1CHRM1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 475 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2022023496-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-02-03 | — | — | WO | claimed |
| WO-2020210643-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2020-10-15 | — | — | WO | claimed |
| CN-108348528-A | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | 科达生物治疗公司 | 2018-07-31 | — | — | CN | claimed |
| EP-3349760-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | Coda Biotherapeutics, Inc. (US) | 2018-07-25 | — | — | EP | claimed |
| WO-2018015915-A1 | A PARENTERAL CONTROLLED RELEASE COMPOSITION OF AN ATYPICAL ANTIPSYCHOTIC AGENT | CADILA HEALTHCARE LIMITED (IN) | 2018-01-25 | — | — | WO | claimed |
| EP-1414466-A1 | COMBINATIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2004-05-06 | — | — | EP | claimed |
| US-20030215531-A1 | Compositions and methods of use for extracts of Rutaceae plants | STOGNIEW MARTIN (US) | 2003-11-20 | — | — | US | claimed |
| EP-1011661-A4 | MEDIATION OF CIRCADIAN RHYTHMS | LUMINIS PTY LTD (AU) | 2003-09-17 | — | — | EP | claimed |
| US-20030078246-A1 | Combinations for the treatment of inflammatory disorders | ZALICUS INC. | 2003-04-24 | — | — | US | claimed |
| WO-2003006026-A1 | COMBINATIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2003-01-23 | — | — | WO | claimed |
| US-20020061339-A1 | Compositions and methods for use of extracts of rutaceae plants | NPI, LLC. | 2002-05-23 | — | — | US | claimed |
| WO-2002026244-A2 | COMPOSITIONS AND METHODS OF USE FOR EXTRACTS OF RUTACEAE PLANTS | NEXT PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | claimed |
| EP-1011661-A1 | MEDIATION OF CIRCADIAN RHYTHMS | LUMINIS PTY. LIMITED (AU) | 2000-06-28 | — | — | EP | claimed |
| US-5877173-A | CLOZAPINE, OLANZAPINE AND FLUPERLAPINE, AND SALTS, ISOMERS AND ANALOGS THEREOF, IS ADMINISTERED. | WASHINGTON UNIVERSITY (US) | 1999-03-02 | — | — | US | claimed |
| WO-1998042331-A1 | MEDIATION OF CIRCADIAN RHYTHMS | LUMINIS PTY. LIMITED (AU) | 1998-10-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078246-A1 | Combinations for the treatment of inflammatory disorders | IL6, FKBP1B, NR3C1 | MAPK1 4399/4885HRH4 288/4885PAK1 4689/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | MAPK1 4129/4885HRH4 235/4885PAK1 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.